Background-Coronary artery disease (CAD) is the major cause of death in patients with type 2 diabetes mellitus. Although demographic and clinical factors associated with extent of CAD in patients with diabetes mellitus have been described, genetic factors have not. We hypothesized that genetic variation in peroxisome proliferator-activated receptor (PPAR) pathway genes, important in diabetes mellitus and atherosclerosis, would be associated with extent of CAD in patients with diabetes mellitus. Methods and Results-We genotyped 1043 patients (702 white, 175 blacks) from the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) genetic cohort for 3351 variants in 223 PPAR pathway genes using a custom targeted-genotyping array. Angiographic end points were determined by a core laboratory. In whites, a single variant (rs1503298) in TLL1 was significantly (Pϭ5.5ϫ10 Ϫ6 ) associated with extent of CAD, defined as number of lesions with percent diameter stenosis Ն20%, after stringent Bonferroni correction for all 3351 single nucleotide polymorphisms. This association was validated in the diabetic subgroups of 2 independent cohorts, the Translational Research Investigating Underlying Disparities in Acute Myocardial Infarction Patients' Health Status (TRIUMPH) postmyocardial infarction registry and the prospective Family Heart Study (FHS) of individuals at risk for CAD.
D iabetes mellitus (DM) currently affects Ͼ17 million people in the United States, and Ϸ1.6 million new cases are diagnosed each year. 1 Among persons with DM, coronary atherosclerosis is highly prevalent and accounts for the majority of deaths. 1 In patients with coronary artery disease (CAD), patients with DM have lower 10-year survival than those without DM, 2 and the extent of CAD predicts mortality. 3 Atherosclerosis in patients with DM has an accelerated phenotype, with more diffuse and extensive disease that shows more rapid progression, suggesting a distinctive pathogenesis. 4 The distinct pathogenesis of the accelerated atherosclerosis observed among patients with DM is poorly understood, 5 and the role of genetic factors is unknown.
Clinical Perspective on p 1434
Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) was a multicenter, randomized clinical trial that investigated the effect of different approaches to the treatment of both CAD and DM on long-term outcomes in patients with type 2 DM. 6, 7 All patients in BARI 2D had DM and CAD suitable for, but not requiring, revascularization. Baseline extent of CAD in BARI 2D was defined angiographically and quantified by a core laboratory. Clinical factors contributing to extent of CAD among patients in BARI 2D, defined as the number of coronary lesions Ն20% diameter stenosis (DS), were recently reported; 8 however, the total variance in extent of CAD explained by baseline clinical factors was Ͻ10%, 8 providing an important rationale for examining the putative role of genetic factors.
Peroxisome-proliferator activated receptor (PPAR) pathway genes are involved in cellular processes relevant to both CAD and DM. Master regulators of lipid and glucose homeostasis, cardiac energy metabolism, vascular inflammation, and cell differentiation, PPARs have been implicated in the development and progression of both type 2 DM and atherosclerosis in animal studies. 9 -12 We therefore hypothesized that investigating genetic variation within the PPAR gene pathway would identify novel genes involved in diabetic atherosclerosis.
Using a custom PPAR pathway gene single nucleotide polymorphism (SNP) microarray containing 3351 SNPs in 223 PPAR pathway genes, we investigated genetic associations of PPAR pathway genes with extent of CAD among patients with DM in the BARI 2D trial. We then sought to validate the discovered associations in 2 additional well-phenotyped cohorts of patients with CAD and DM.
Methods

Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) Cohort and Baseline Phenotypic Data
Eligibility criteria for BARI 2D have previously been described. 6, 7 Patients with type 2 DM having angiographically documented CAD involving at least 1 major epicardial coronary artery (Ն50% DS with a positive stress test or Ն70% DS with classic angina) suitable for treatment with either medical therapy or coronary revascularization were eligible for inclusion. 6, 7 Exclusion criteria included significant left main disease (Ն50% DS), class III or IV congestive heart failure, and coronary revascularization within the preceding 12 months. All patients underwent coronary angiography, and the angiograms were reviewed by a central core laboratory (Stanford University) with a standard protocol used in previous trials and masked to patient randomization or intended revascularization strategy. 7, 8 This assessment included quantifying the number and percent DS of each lesion, its location in the coronary tree using the BARI modification of the Coronary Artery Surgery Study map, and the lesion morphology according to the American College of Cardiology/American Heart Association classification scheme. 8 Percent DS was the ratio of the minimum diameter divided by the reference diameter (the mean of the proximal and distal diameter of the normal-appearing artery adjacent to the lesion). All lesions Ն20% DS were counted. In addition to number of lesions, total myocardial jeopardy index was calculated. The myocardial jeopardy index was calculated as the percentage of the myocardium that was jeopardized by lesions Ն50% DS in any of the 3 main coronary arteries or their branches. 8, 13 In accordance with the published analysis of clinical predictors of extent of CAD in BARI 2D, 8 number of coronary lesions Ն20% DS was selected to represent the overall extent of atherosclerotic CAD; additional angiographic variables were included to represent the extent of severe atherosclerotic CAD (number of lesions Ն70% DS and myocardial jeopardy index).
Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) Genetic Cohort
A total of 2368 patients were enrolled in BARI 2D from January 2001 through March 2005. Of these, 1439 BARI 2D patients consented to genetic analysis; 1072 genomic samples (702 whites, 175 blacks) were available for genotyping (353 samples from Brazil were not available because of international restrictions on DNA shipment). To determine whether the genetic cohort was representative of the entire BARI 2D cohort, clinical covariates and association with number of lesions Ն20% DS were determined for the entire genetic cohort (not stratified by race). Using the same clinical covariates and the same analytic strategy (variable entry and retention criteria; entry PϽ0.15, retain PϽ0.05; age, and sex included regardless of statistical significance) used in the entire cohort, 8 we determined the magnitude of individual variables associated with extent of CAD (presented as semipartial correlation coefficients). 15 and all patients had an elevated troponin blood test. Thirty-one percent of TRIUMPH patients had DM on enrollment. Extent of CAD was determined by angiography and defined as the number of vessels with Ն20% DS. We genotyped 386 whites using the PPAR pathway custom array constituting the genetic cohort for the present analysis. The study was approved by the Institutional Review boards of all participating institutions, and written informed consent was provided by each participant. A separate consent form for the acquisition of blood for genetic analysis was signed by each participant.
Validation Cohorts
Translational Research Investigating Underlying Disparities in Acute Myocardial Infarction Patients' Health Status Study
Family Heart Study
The Family Heart Study (FHS) has been described in detail. 16, 17 Briefly, adults (45 to 69 years of age) were recruited from 1 of 3 studies: the Framingham study, the Utah study, and 2 Atherosclerosis Risk in Communities sites. Subjects and their family members were either randomly selected or selected because they had a high relative risk of coronary heart disease. 17 Of these, 14% had DM. The cardiac computed tomography subset of FHS (the FHS Subclinical Atherosclerosis Network) recruited patients and their family members previously enrolled in FHS who had been genotyped by genomewide association study to undergo cardiac computed tomography to determine the extent of coronary artery and aortic calcification. 16, 17 Coronary artery calcification was determined by a core laboratory (Wake Forest University Health Sciences, Winston Salem, NC) as previously described. 16, 17 In brief, 2 sequential scans were performed 1 minute apart; the amount of calcium was quantified by the Agatston scoring method adjusted for slice thickness; and the total coronary artery calcification score was calculated as the sum of the Agatston scores from each scan and then averaged. We genotyped 974 whites with the Illumina 550K SNP array.
Genotyping and Custom Array
DNA was isolated and extracted with the Puregene genomic DNA purification kit (Gentra, Minneapolis, MN). DNA (4 g) was genotyped using a custom-designed PPAR pathway-targeted genotyping 3K array containing 3351 SNPs in 223 genes within the PPAR pathway and 100 SNPs, allowing identification of ethnic origin by mapping by admixture linkage disequilibrium (Affymetrix, Santa Clara, CA; Table I in the online-only Data Supplement). 18
Method of Selection of Genes on Custom Array
The PPAR pathway genes were selected if they met 1 of 2 criteria: were identified as a PPAR pathway gene in the published literature or showed Ͼ2-fold upregulation or downregulation in in vitro gene expression profiling experiments performed with mouse hearts overexpressing PPAR␣ compared with nontransgenic littermates (data graciously provided by Dr Daniel P. Kelly, Burnham Institute for Medical Research, Orlando, FL).
Method of Selection of Single Nucleotide Polymorphisms on Custom Array
The SNPs were chosen from HapMap data. The projected populations selected for tagging were Africans and whites, with a bias toward white coverage. A tagging SNP approach (from 5 kb upstream of the gene to 5 kb downstream of the gene; minor allele frequency of Ն10% in white and black populations; the method of Carlson et al 19 was used to select tagging SNPs; r 2 Ͼ0.8 required) was used. If a tagging SNP was in a large bin (containing Ն5 SNPs with r 2 Ͼ0.8), we included 2 tagging SNPs on the array to ensure maximal data acquisition (although genotyping only 1 tagging SNP is highly efficient, if it fails to genotype, a large amount of data could potentially be lost). In addition to the tagging SNPs, the array also includes all nonsynonymous coding SNPs in each gene (regardless of minor allele frequency). The SNP coverage provided by the final panel was 8500/Ϸ10 000 whites and 7000/Ϸ11 000 Yorubans.
Genotyping Quality Control Data
Data completeness was 99.64% and repeatability was 100%. To ensure high-quality data and to minimize false-positive results, filtering criteria were set as follows: genotype call rate Ն0.80 per SNP, minor allele frequency Ն0.01, and P value for Hardy-Weinberg equilibrium test Ն0.0001. Using the PLINK analysis program (version 1.06), we identified 5 white subjects whose reported sex did not match the sex estimated from the X chromosome data. These 5 samples were excluded from further analysis. Cluster analysis implemented in PLINK was used for screening any evidence of subtle population stratifications based on pairwise identity-bystate sharing distance among all possible pairs of the SNPs. Across the samples of the BARI 2D genetic cohort, 4 well-separated subgroups correlated with self-reported ethnic groups, and the 2 major groups of blacks and whites were clearly distinguished. In blacks, no further population stratification was detected according to multidimensional scaling plots ( Figure I in the online-only Data Supplement). In whites, subtle clustering was noted; we therefore estimated 10 principal components using Eigenstrat.
Statistical Methods
Clinical Covariates
The primary end point for our analysis was number of lesions Ն20% DS documented on the coronary angiogram. Myocardial jeopardy index and number of lesions Ն70% DS were also determined for variant(s) achieving significance in replication cohorts. Number of lesions and myocardial jeopardy index were evaluated as continuous variables, with kernel density estimators used to plot their overall distributions. Continuous variables were compared by Student t tests or Wilcoxon tests (depending on distributional properties); categorical variables were compared by 2 tests. Stepwise linear regression was used to identify baseline factors associated with number of lesions (log transformed) and myocardial jeopardy index.
Single Nucleotide Polymorphism Association
To prevent confounding from racial admixture, we performed our analyses separately in our 2 largest racial groups (whites, nϭ702; blacks, nϭ175). Single SNP associations for the number of lesions Ն20% DS were tested in general linear regression analyses using an additive genetic model. Age, sex, body mass index, and prior revascularization were included in the model as covariates. Significance level was 1.5ϫ10 Ϫ5 using stringent Bonferroni correction for all 3351 SNPs.
Validation
We validated putative statistically significant associations in the 2 separate cohorts of patients systematically assessed for extent of CAD described above, TRIUMPH and FHS. Because the significant association was observed in white BARI 2D subjects, white TRIUMPH and FHS subjects were used for validation. None of the subjects were related in TRIUMPH. Because FHS had related subjects, we used mixed models to take family structure into account. Values of PϽ0.05 were considered statistically significant for validation analyses. Statistical analyses were performed with SAS 9.1 (SAS Institute Inc, Cary, NC), and plots were generated by R 2.3.1 (CRAN, the comprehensive R archive network).
Results
The Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) Genetics Cohort
The baseline characteristics of the patients making up the genetic cohort of BARI 2D were similar to those of the entire group (Table) . The primary end point representing the extent of CAD (number of coronary lesions Ն20% DS) was the same in the BARI 2D genetic cohort (mean number of coronary lesions Ն20% DS ϭ 4.6Ϯ2.2) and in the entire BARI 2D cohort (mean number of coronary lesions Ն20% DS ϭ 4.6Ϯ2.3). To further confirm that the extent of CAD in the genetics subgroup was representative of the entire cohort, the magnitude of association between clinical covariates and number of coronary lesions Ն20% DS was compared between the 2 groups. As shown in Figure 1 , individual clinical covariates in the BARI 2D genetic cohort showed correlations with the extent of CAD similar to those of the entire BARI 2D cohort. Similar to the entire BARI 2D cohort, female sex, black race, higher body mass index, and higher 30-second pulse were associated with less extensive CAD, whereas older age, longer duration of DM, hypertension, and higher tissue-type plasminogen activator antigen levels were associated with more extensive CAD.
Peroxisome Proliferator-Activated Receptor Pathway Single Nucleotide Polymorphism Associations With Extent of Coronary Artery Disease
To prevent confounding from racial admixture, we performed our analyses separately in our 2 largest racial groups (whites, nϭ702; blacks, nϭ175). In white BARI 2D subjects, single SNP analysis identified 1 SNP (rs1503298) that was highly significantly associated (Pϭ5.5ϫ10 Ϫ6 ) with number of coronary lesions Ն20% DS (Figure 2 ), even after stringent Bonferroni correction for all 3351 SNPs. This SNP is located in intron 12 of the gene that encodes Tolloid-like 1 (TLL1), a metalloproteinase that regulates bone morphogenetic protein-2 (BMP-2) and transforming growth factor-␤. This association remained significant after inclusion of all baseline clinical covariates and principal components in the model. The meanϮSE residual of number of lesions Ն20% by TLL1 rs1503298 genotype after adjustment for age, sex, and body mass index in white BARI 2D subjects is shown in Figure 3A .
To put these data into a clinically relevant context, an average BARI 2D subject (a 63-year-old man with a body mass index of 30 kg/m 2 ) with the TT genotype would have 4.43 coronary lesions Ն20% DS; with the CT genotype, 5.02 coronary lesions Ն20% DS; and with the CC genotype, 5.46 coronary lesions Ն20% DS ( Figure 3B ). Of note, in general linear regression modeling, this SNP explained more variance of the phenotype (number of coronary lesions Ն20% DS) than the previously determined clinical factors. TLL1 rs1503298 explained 2.75% of the variance compared with sex (1.61%), age (0.12%), and body mass index (0.01%). Subjects with the TLL1 rs1503298 CT genotype had 22% more coronary lesions Ն20% DS compared with those with the TT genotype, and those with the CC genotype had 37% more coronary lesions Ն20% DS.
Table. Baseline Characteristics of the Entire Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) Cohort, the BARI 2D Genetic Cohort, and the White Subgroups of BARI 2D, Translational Research Investigating Underlying Disparities in Acute Myocardial Infarction Patients' Health Status (TRIUMPH), and Family Heart Study (FHS)
In the smaller subgroup of black BARI 2D subjects (nϭ175), no SNP was found to be significantly associated with number of coronary lesions Ն20% DS after stringent Bonferroni correction for all 3351 SNPs. This included TLL1 rs1503298 (Pϭ0.25).
Validation
For validation, the genetic association observed in BARI 2D was tested in both the overall group and the diabetic subgroups of 2 independent cohorts of patients with CAD, TRIUMPH and FHS. These validation cohorts were chosen because both TRIUMPH and FHS were independent populations with detailed information on extent of CAD by quanti-tative imaging studies, both had detailed information on subjects with and without carefully defined DM, both had extensive phenotypic data to allow consistent adjustment for covariates, and both were genotyped for relevant polymorphisms. Validation analyses were performed on (white) subjects with and without DM within these same cohorts to obtain insight into whether the association was specific to individuals with DM. When the same model was applied in TRIUMPH with the identical SNPs used in BARI 2D, a significant association with extent of CAD was selectively demonstrated for TLL1 rs1503298 among patients with DM (nϭ98; Pϭ3.3ϫ10 Ϫ2 ) but not in the overall cohort (nϭ386; Pϭ1.8ϫ10 Ϫ1 ). A congruent trend was found in FHS with the use of a less sensitive measure of CAD extent. The association between rs1503298 and extent of CAD defined by coronary calcium score was demonstrated selectively in FHS individuals with DM (nϭ139; Pϭ8.5ϫ10 Ϫ2 ) but did not replicate in the larger FHS cohort (nϭ974; Pϭ5.7ϫ10 Ϫ1 ).
Associations With Severe Coronary Artery Disease
We also investigated whether the TLL1rs1503298 variant was associated with the extent of severe CAD and myocardial jeopardy index in BARI 2D, variables previously associated with mortality in other studies. 3, 13 TLL1 rs1503298 was significantly associated with both number of coronary lesions Ն70% DS (Pϭ3.7ϫ10 Ϫ2 ) and myocardial jeopardy index (Pϭ8.7ϫ10 Ϫ4 ; Figure 4 ).
Discussion
Using a gene pathway microarray approach, we have identified a novel PPAR pathway genetic polymorphism that is significantly associated with extent of CAD in patients with DM. The TLL1 rs1503298 variant, located in intron 12 of TLL1, showed associations with rigorous and objectively derived measures of atherosclerotic coronary disease in BARI 2D and explained more variance of the phenotype than the previously determined clinical factors. The association of extent of CAD observed with TLL1 rs1503298 in BARI 2D was validated by replication in the diabetic patients in 2 independent populations, TRIUMPH and FHS.
The association of TLL1 rs1503298 with extent of CAD was observed among white patients with type 2 DM in the BARI 2D trial, in whom clinically stable CAD was defined and quantified by core laboratory interpretation of coronary angiograms. This association was validated by replication in the white diabetic subgroups of 2 independent populations with CAD: the TRIUMPH cohort, in whom CAD in patients with acute myocardial infarction was defined angiographically, and the FHS cohort, in whom individuals at high risk of CAD had their extent of coronary artery calcification deter-mined by computed tomography scanning. The observation that this variant was reproducibly associated with extent of disease quantified by disparate methods among individuals with disparate clinical manifestations supports a potential role for this genetic polymorphism in the pathogenesis of diabetic atherosclerosis. Further reinforcing the clinical relevance of the association between this SNP and CAD in patients with DM, the TLL1 rs1503298 polymorphism showed strong associations not only with the primary end point of number of lesions Ն20% DS but also with number of angiographically severe (Ն70% DS) lesions and with myocardial jeopardy index, a semiquantitative method used to estimate the amount of potential myocardial ischemia attributable to the location and severity of coronary lesions in an individual; these measures of extent of severe CAD have previously been shown to correlate with prognosis in patients with CAD. 3, 13 To the best of our knowledge, this is the first demonstration of a significant association of genetic variation specifically with extent of the atherosclerotic disease that develops among patients with DM, in which atherosclerosis has been known to display a distinctively aggressive phenotype. 20 -22 The observation of an association between extent of CAD in patients with DM and this particular gene in the PPAR pathway-regulated processes is noteworthy. TLL1 encodes a protein, Tolloid-like 1 (TLL1), that has been identified within the cascade of cellular processes related to vascular inflammation and calcification. Because vascular calcification is a prominent feature of the phenotype of diabetic atherosclerosis, 23 genetic variability in TLL1 may have strong biological plausibility as a contributor to its pathogenesis. 23 TLLI is a metalloproteinase that cleaves the BMP-2 antagonists Chor- din and gremlin, thereby upregulating BMP-2/4 pathway genes that promote inflammation and extracellular matrix neogenesis. 24, 25 BMP-2 itself is an important mediator of tissue calcification, and endothelial BMP-2 expression can be upregulated by vascular oxidative stress, intravascular pressure, and elevated glucose. 26 -29 BMP-2 appears to play a critical role in programming the phenotype of the calcifying vascular cell, the mural cell type that directs osteogenic mineralization in the vessel wall. 24,25,27,30 -32 Moreover, TLL1 is also a member of the BMP-1-related activators of the procollagen C-proteinase enhancer. 33, 34 Because TLL1 is at the intersection of the BMP-2/4 and frizzled-related protein-2 signals that drive collagen deposition, TLL1 is also likely to be a critical regulator of collagenous matrix deposition, a hallmark of robust calcification processes in cardiovascular tissues and in bone. 33, 34 BMP-2 is upregulated in human atherosclerotic plaques 26, 35 and has been identified as a key multifunctional regulator of vascular calcium accrual in atherosclerosis and diabetic arteriosclerosis. 36, 37 Thus, TLL1 has a direct link to fundamental cellular processes involved in vascular calcification, a widely recognized feature of atherosclerosis that is characteristically increased in patients with DM compared with those without DM. 4,20 -22 Previous genetic association studies have observed associations between polymorphisms of PPAR pathway genes and the risk of developing type 2 DM, obesity, insulin resistance, abnormal lipid profiles, and cardiovascular disease in European and American populations (reviewed elsewhere 9, 38 ). In separate candidate gene studies, an SNP in intron 7 of the PPAR␣ gene (PPARA IVS7 2498) 39 and 2 SNPs in PPARG (the gene encoding PPAR␥) were associated with increased risk of myocardial infarction in patients with type 2 DM. 40 Also using a candidate gene approach, Regieli et al 41 reported an association between the Pro12Ala variant (rs1801282) of PPARG and both angiographic extent of CAD and 10-year risk of ischemic events, including death, among 679 participants in the Regression Growth Evaluation Statin Study (REGRESS) without differentiation of result by diabetic status. This association was not confirmed in other studies. 42 Of note, in the present analysis, the IVS7 2498 SNP in PPARA and the Pro12Ala polymorphism in PPARG (both present on the PPAR pathway array used) were not identified as variants with a significant association with extent of CAD in the BARI 2D cohort.
Our findings should be considered in the context of several potential limitations. First, to prevent confounding from racial admixture, we performed analyses in the largest racial groups (whites and black) separately. The association between TLL1rs1503298 and extent of CAD was observed among white patients with DM. Similar analyses did not confirm an association between TLL1 and extent of CAD among black participants in BARI 2D, although the smaller sample size may have limited the power to detect a significant relationship if present, or there may be different patterns of linkage disequilibrium between TLL1 rs1503298 and the causal variant in different ethnic groups. Our findings therefore cannot be extrapolated to other racial groups and should be examined independently in adequately powered, racially characterized cohorts, particularly given the burden of DM and CAD in black and Hispanic patients. In addition, this study used the genetic cohort of BARI 2D, and although the genetic cohort had baseline characteristics similar to those of the overall BARI 2D cohort, selection bias is possible. However, because patients (and their treating physicians) were unaware of their genetic code, it is unlikely that there was a direct association between genotype and participation in the genetic cohort of BARI 2D to make selection bias significantly problematic. Furthermore, it should be noted that diabetic patients with the most extensive, or unstable, CAD for whom immediate revascularization was considered clinically indicated were excluded from BARI 2D by design. Therefore, the observed association has not been tested in this potentially important subgroup of patients with DM and CAD. Finally, it should be noted that the mechanisms of action of TLL1 could potentially be via a pathway other than PPAR. Without further confirmation, caution is warranted in attributing the observed association to a direct or indirect effect of PPAR activation.
Conclusions
Using a gene pathway microarray approach, we identified and validated a novel PPAR pathway gene variant, TLL1 rs1503298, that is significantly associated with extent of CAD specifically in white patients with DM. The reproducibility of the observed association across populations, despite varied clinical manifestations of CAD and varied methods of quantifying the extent of atherosclerosis, underscores its potential importance and relevance to the fundamental pathophysiology of diabetic atherosclerosis. Moreover, the physiological pathways affected by this genetic variant may provide novel targets for further investigation and therapeutic intervention to address the accelerated rate of progression and the high risk of adverse events associated with CAD in patients with DM.
